AVXL
Anavex Life Sciences Corp.
Price Chart
No historical data available
Latest Quote
$2.99
| Previous Close | $3.13 |
| Open | $3.12 |
| Day High | $3.13 |
| Day Low | $2.96 |
| Volume | 893,387 |
Stock Information
| Shares Outstanding | 92.70M |
| Cash Equivalents | $118.33M |
| Net Income | $-13.02M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $277.16M |
| EPS (TTM) | $-0.14 |
| Exchange | NMS |
Recent Price History
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.
đ° Latest News
Income Statement (Annual)
| Metric | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $0 | $0 | $964,000 | $0 |
| Total Expenses | $51,371,000 | $52,802,000 | $55,738,000 | $50,986,000 |
| Other Income Expense | $316,000 | $2,480,000 | $2,678,000 | $2,419,000 |
| Other Non Operating Income Expenses | $648,000 | $2,291,000 | $2,718,000 | $3,323,000 |
| Net Non Operating Interest Income Expense | $4,678,000 | $7,320,000 | $5,555,000 | $947,000 |
| Interest Expense Non Operating | $0 | $0 | $964,000 | $0 |
| Operating Expense | $51,371,000 | $52,802,000 | $55,738,000 | $50,986,000 |
| Other Operating Expenses | $-37,000 | $-75,000 | $-25,000 | - |
| General And Administrative Expense | $13,816,000 | $11,039,000 | $12,046,000 | $13,070,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-46,377,000 | $-43,002,000 | $-47,505,000 | $-47,978,000 |
| Net Interest Income | $4,678,000 | $7,320,000 | $5,555,000 | $947,000 |
| Interest Income | $4,678,000 | $7,320,000 | $6,519,000 | $947,000 |
| Normalized Income | $-46,045,000 | $-43,191,000 | $-47,465,000 | $-47,263,840 |
| Net Income From Continuing And Discontinued Operation | $-46,377,000 | $-43,002,000 | $-47,505,000 | $-47,978,000 |
| Total Operating Income As Reported | $-51,408,000 | $-52,877,000 | $-55,763,000 | $-50,986,000 |
| Net Income Common Stockholders | $-46,377,000 | $-43,002,000 | $-47,505,000 | $-47,978,000 |
| Net Income | $-46,377,000 | $-43,002,000 | $-47,505,000 | $-47,978,000 |
| Net Income Including Noncontrolling Interests | $-46,377,000 | $-43,002,000 | $-47,505,000 | $-47,978,000 |
| Net Income Continuous Operations | $-46,377,000 | $-43,002,000 | $-47,505,000 | $-47,978,000 |
| Pretax Income | $-46,377,000 | $-43,002,000 | $-47,505,000 | $-47,620,000 |
| Interest Income Non Operating | $4,678,000 | $7,320,000 | $6,519,000 | $947,000 |
| Operating Income | $-51,371,000 | $-52,802,000 | $-55,738,000 | $-50,986,000 |
| Per Share | ||||
| Diluted EPS | $-0.54 | $-0.52 | $-0.60 | $-0.62 |
| Basic EPS | $-0.54 | $-0.52 | $-0.60 | $-0.62 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $-189,840 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-46,045,000 | $-43,191,000 | $-46,501,000 | $-46,716,000 |
| Total Unusual Items | $-332,000 | $189,000 | $-40,000 | $-904,000 |
| Total Unusual Items Excluding Goodwill | $-332,000 | $189,000 | $-40,000 | $-904,000 |
| EBITDA (Bullshit earnings) | $-46,377,000 | $-43,002,000 | $-46,541,000 | $-47,620,000 |
| EBIT | $-46,377,000 | $-43,002,000 | $-46,541,000 | $-47,620,000 |
| Diluted Average Shares | $85,289,447 | $83,468,049 | $79,787,596 | $76,909,993 |
| Basic Average Shares | $85,289,447 | $83,468,049 | $79,787,596 | $76,909,993 |
| Diluted NI Availto Com Stockholders | $-46,377,000 | $-43,002,000 | $-47,505,000 | $-47,978,000 |
| Gain On Sale Of Security | $-332,000 | $189,000 | $-40,000 | $-904,000 |
| Research And Development | $37,592,000 | $41,838,000 | $43,717,000 | $37,916,000 |
| Selling General And Administration | $13,816,000 | $11,039,000 | $12,046,000 | $13,070,000 |
| Other Gand A | $13,816,000 | $11,039,000 | $12,046,000 | $13,070,000 |
| Tax Provision | - | $0 | $7,000 | $358,000 |
Balance Sheet (Annual)
| Metric | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $94,869,000 | $120,263,000 | $141,852,000 | $142,491,000 |
| Total Assets | $103,815,000 | $135,567,000 | $154,386,000 | $152,705,000 |
| Total Non Current Assets | $0 | $0 | $0 | $0 |
| Current Assets | $103,815,000 | $135,567,000 | $154,386,000 | $152,705,000 |
| Other Current Assets | $429,000 | $931,000 | $653,000 | $354,000 |
| Receivables | $809,000 | $2,449,000 | $2,709,000 | $3,193,000 |
| Taxes Receivable | $809,000 | $2,449,000 | $2,709,000 | $3,193,000 |
| Cash Cash Equivalents And Short Term Investments | $102,577,000 | $132,187,000 | $151,024,000 | $149,158,000 |
| Cash And Cash Equivalents | $102,577,000 | $132,187,000 | $151,024,000 | $149,158,000 |
| Prepaid Assets | - | - | - | $354,162 |
| Current Deferred Assets | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $8,946,000 | $15,304,000 | $12,534,000 | $10,214,000 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 | $0 |
| Current Liabilities | $8,946,000 | $15,304,000 | $12,534,000 | $10,214,000 |
| Current Deferred Liabilities | $805,000 | $842,000 | $917,000 | $444,000 |
| Payables And Accrued Expenses | $6,579,000 | $12,935,000 | $10,257,000 | $8,472,000 |
| Payables | $4,249,000 | $9,627,000 | $4,322,000 | $3,825,000 |
| Accounts Payable | $4,249,000 | $9,627,000 | $4,322,000 | $3,825,000 |
| Equity | ||||
| Common Stock Equity | $94,869,000 | $120,263,000 | $141,852,000 | $142,491,000 |
| Total Equity Gross Minority Interest | $94,869,000 | $120,263,000 | $141,852,000 | $142,491,000 |
| Stockholders Equity | $94,869,000 | $120,263,000 | $141,852,000 | $142,491,000 |
| Retained Earnings | $-382,448,000 | $-336,071,000 | $-293,069,000 | $-245,564,000 |
| Other | ||||
| Ordinary Shares Number | $86,668,521 | $84,795,517 | $82,066,511 | $77,942,815 |
| Share Issued | $86,668,521 | $84,795,517 | $82,066,511 | $77,942,815 |
| Tangible Book Value | $94,869,000 | $120,263,000 | $141,852,000 | $142,491,000 |
| Invested Capital | $94,869,000 | $120,263,000 | $141,852,000 | $142,491,000 |
| Working Capital | $94,869,000 | $120,263,000 | $141,852,000 | $142,491,000 |
| Total Capitalization | $94,869,000 | $120,263,000 | $141,852,000 | $142,491,000 |
| Additional Paid In Capital | $477,230,000 | $456,249,000 | $434,839,000 | $387,977,000 |
| Capital Stock | $87,000 | $85,000 | $82,000 | $78,000 |
| Common Stock | $87,000 | $85,000 | $82,000 | $78,000 |
| Current Deferred Revenue | $805,000 | $842,000 | $917,000 | $444,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $1,562,000 | $1,527,000 | $1,360,000 | $1,298,000 |
| Current Accrued Expenses | $2,330,000 | $3,308,000 | $5,935,000 | $4,647,000 |
| Preferred Stock | - | - | - | $0 |
Cash Flow Statement (Annual)
| Metric | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-39,044,000 | $-30,812,000 | $-27,785,000 | $-24,238,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-39,044,000 | $-30,812,000 | $-27,785,000 | $-24,238,000 |
| Cash Flow From Continuing Operating Activities | $-39,044,000 | $-30,812,000 | $-27,785,000 | $-24,238,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $9,198,000 | $11,284,000 | $27,875,000 | $20,985,000 |
| Financing Cash Flow | $9,434,000 | $11,975,000 | $29,651,000 | $21,288,000 |
| Cash Flow From Continuing Financing Activities | $9,434,000 | $11,975,000 | $29,651,000 | $21,288,000 |
| Net Common Stock Issuance | $9,198,000 | $11,284,000 | $27,875,000 | $20,985,000 |
| Common Stock Issuance | $9,198,000 | $11,284,000 | $27,875,000 | $20,985,000 |
| Net Other Financing Charges | - | - | - | $-707,000 |
| Other | ||||
| Income Tax Paid Supplemental Data | $125,000 | $300,000 | $136,000 | $327,000 |
| End Cash Position | $102,577,000 | $132,187,000 | $151,024,000 | $149,158,000 |
| Beginning Cash Position | $132,187,000 | $151,024,000 | $149,158,000 | $152,108,000 |
| Changes In Cash | $-29,610,000 | $-18,837,000 | $1,866,000 | $-2,950,000 |
| Proceeds From Stock Option Exercised | $2,943,000 | $691,000 | $1,776,000 | $1,010,000 |
| Change In Working Capital | $-4,216,000 | $2,752,000 | $2,505,000 | $5,361,000 |
| Change In Other Working Capital | $-37,000 | $-75,000 | $473,000 | - |
| Change In Payables And Accrued Expense | $-6,321,000 | $2,845,000 | $1,847,000 | $-584,000 |
| Change In Accrued Expense | $-943,000 | $-2,460,000 | $1,350,000 | $330,000 |
| Change In Payable | $-5,378,000 | $5,305,000 | $497,000 | $-914,000 |
| Change In Account Payable | $-5,378,000 | $5,305,000 | $497,000 | $-914,000 |
| Change In Prepaid Assets | $502,000 | $-278,000 | $-299,000 | $1,000 |
| Change In Receivables | $1,640,000 | $260,000 | $484,000 | $5,944,000 |
| Stock Based Compensation | $11,549,000 | $9,438,000 | $16,370,000 | $18,379,000 |
| Net Income From Continuing Operations | $-46,377,000 | $-43,002,000 | $-47,505,000 | $-47,978,000 |
| Other Non Cash Items | - | - | $845,000 | - |